EMVI-positive stage ii rectal cancer has similar clinical outcomes as stage iii disease following pre-operative chemoradiotherapy

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 858-863

  Chand, M ^a,b,c   Bhangu, A ^a,b,c   Wotherspoon, A ^a,c   Stamp, G W H ^a,c   Swift, R I ^b   Chau, I ^a   Tekkis, P P ^a,c   Brown, G ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant chemotherapy; EMVI; Rectal cancer; Stage II; Venous invasion

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTRAMURAL VENOUS INVASION; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECTUM CANCER; TUMOR INVASION; VERY ELDERLY; ADJUVANT THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECTAL NEOPLASMS; TREATMENT OUTCOME;

AGED; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84897098108     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu029     Document Type: Article

References (30)

1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17:1471-1474.
2. Newland RC, Dent OF, Lyttle MN et al. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer. 1994;73:2076-2082.
3. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010;21:1743-1750.
4. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012;23:2479-2516.
5. Petersen SH, Harling H, Kirkeby LT et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;3: CD004078.
6. Smith NJ, Barbachano Y, Norman AR et al. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008;95:229-236.
7. Michelassi F, Block GE, Vannucci L et al. A 5-to 21-year follow-up and analysis of 250 patients with rectal adenocarcinoma. Ann Surg 1988;208:379-389.
8. Freedman LS, Macaskill P, Smith AN. Multivariate analysis of prognostic factors for operable rectal cancer. Lancet 1984;2:733-736.
9. Talbot IC, Ritchie S, Leighton M et al. Invasion of veins by carcinoma of rectum: method of detection, histological features and significance. Histopathology 1981;5:141-163.
10. Ptok H, Meyer F, Steinert R et al. No prognostic impact of isolated lymphovascular invasion after radical resection of rectal cancer-results of a multicenter observational study. Int J Colorectal Dis 2007;22:749-756.
11. Talbot IC, Ritchie S, Leighton MH et al. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980;67:439-442.
12. Brown CF. Visceral metastasis from rectal carcinoma. Surg Gynecol Obstet 1938; 66:611-621.
13. Williams GT, Quirke P, Shepherd NA. Dataset for Colorectal Cancer, 2nd edition. 2007. Appendix C. London, UK. http://www.rcpath.org/resources/worddocs/G049ColorectalDatasetAppendixC-Sep07.doc. (10 August 2013, date last accessed).
14. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
15. Bosset JF, Calais G, Daban A et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer 2004;40:219-224.
16. Jass JR, Atkin WS, Cuzick J et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-459.
17. Sasaki O, Atkin WS, Jass JR. Mucinous carcinoma of the rectum. Histopathology 1987;11:259-272.
18. Messenger DE, Driman DK, Kirsch R. Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome. Hum Pathol 2012;43:965-973.
19. Chand M, Swift RI, Tekkis PP et al. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer 2014;110:19-25.
20. Chand M, Bhoday J, Bhome R et al. mrEMVI status should be used in addition to pEMVI for treatment decision making in rectal cancer to prevent under-reporting of extramural venous invasion. Eur J Surg Oncol 2013;39: S66.
21. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992;10:549-557.
22. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-29.
23. Wolmark N. Adjuvant therapy for colorectal cancer: the NSABP clinical trials. Adv Exp Med Biol 1988;244:261-266.
24. Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370: 2020-2029.
25. James RD, Donaldson D, Gray R et al. Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br J Surg 2003;90:1200-1212.
26. Valentini V, Aristei C, Glimelius B et al. Multidisciplinary Rectal Cancer Management:2nd European Rectal Cancer Consensus Conference (EURECACC2). Radiother Oncol 2009;92:148-163.
27. Smith NJ, Shihab O, Arnaout A et al. MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol 2008;191: 1517-1522.
28. Shihab OC, Taylor F, Salerno G et al. MRI predictive factors for long-term outcomes of low rectal tumours. Ann Surg Oncol 2011;18:3278-3284.
29. Taylor FG, Quirke P, Heald RJ et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011;253:711-719.
30. Petersen VC, Baxter KJ, Love SB et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002;51:65-69.